At a glance
- Originator Eisai Co Ltd
- Class
- Mechanism of Action Lipoxygenase inhibitors; Thromboxane synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Ulcerative colitis